There were no statistically significant differences between the 2 study arms with regard to : 1 ) peripheral neurotoxicity , as assessed using both the EORTC-QLQ-CIPN20 ( P = .21 ) and the CTCAE scales ( P = .449 for grade 2 neurotoxicity ; P = .039 for time to development of grade 2 neuropathy , in favor of the placebo ) ; 2 ) the degree of paclitaxel acute pain syndrome ( P = .30 for patients who received paclitaxel every 3-4 weeks and P = .002 , in favor of the placebo , for patients who received weekly paclitaxel ) ; 3 ) the time to disease progression ( P = .63 ) ; or 4 ) apparent toxicities .